2 recruiting. 1 Phase 1, 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Recruiting 1 |
| Phase 2 | 1 | Recruiting 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Vega Therapeutics, Inc: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate Subcutaneous (SC) VGA039 in Patients With Von Willebrand Disease (VWD) VGA039 - Von Willebrand Disease (VWD) | Phase 3 | Recruiting | Vega Therapeutics, Inc | 60 | 2025-10-15 | 2026-09-14 |
| Study of VGA039 in Healthy Volunteers and Patients With Von Willebrand Disease (VIVID) VGA039, Placebo - Von Willebrand Diseases | Phase 1 / Phase 2 | Recruiting | Vega Therapeutics, Inc | 116 | 2023-03-16 | 2025-08-26 |
von Willebrand Diseases (2) · Blood Coagulation Disorders (1) · Hemostatic Disorders (1)
Australia (2) · Austria (2) · Brazil (2) · South Africa (2) · United Kingdom (2) · United States (2) · Canada (1) · Georgia (1) · Germany (1) · India (1) · Ireland (1) · Italy (1)